Skip to main content

Table 3 Subgroup analysis of HIV+TB (n = 63) against nevirapine trough concentrations at 28 days

From: The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment

S.N.

Subgroups

Number

of cases

Mean Nevirapine concentrations at

day 28 (μg/ml/)

Standard

deviation

P value

1

HIV+TB (Cases)

63

2.78

1.60

--

2a

Cases alive at the end Of 48 weeks

49

2.80

1.53

0.85

2b

Cases who died during the study period

13

2.70

1.92

 

3a

Cases with undetectable viral loads at the end of 24 weeks

28

3.08

1.76

0.19

3b

Cases who died or had detectable viral loads at the end of 24 weeks

32

2.52

1.48

 

4a

Cases with undetectable viral load at the end of 24 weeks

28

3.08

1.76

0.14

4b

Cases who were alive but had detectable Viral load at the end of 24 weeks

19

2.40

1.14